Our findings demonstrate that CDH17-targeting CAR-NK cells effectively eliminate multiple GI cancers in both in vitro cell models and in vivo tumor models, including cell-derived xenograft (CDX) and patient-derived xenograft (PDX). The gene discussed is CDH17; the disease is neoplasm.